Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Tsubota Laboratory Incorporated

Market Cap 7.58B 47.35M 40.81M 37.56M 35.24M 66.19M 4.48B 66.85M 444M 173M 2.19B 178M 174M P/E Ratio 2024
-14.1x
P/E Ratio 2025 49.7x
Enterprise Value 6.14B 38.31M 33.02M 30.39M 28.51M 53.55M 3.62B 54.09M 359M 140M 1.77B 144M 141M EV / Sales 2024
10.8x
EV / Sales 2025 6.38x
Free-Float
27.85%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 71 01/02/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/02/2019
Director/Board Member 70 01/06/2020
Director/Board Member 55 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 35.26M
+0.96%+1.16%-12.97%-12.33% 43.03B
+4.02%+7.79%+294.33%+536.67% 32.71B
-1.69%-2.89%+13.70%-17.71% 30.29B
+1.41%-0.96%-0.53%+33.41% 29.4B
+1.16%+9.79%+14.27%+22.28% 25.08B
+2.40%+8.49% - - 13.54B
+0.03%+2.10%+56.75%+111.91% 13.35B
-1.09%-2.31%+5.07%+5.00% 12.97B
+0.93%+0.57%+107.81%+77.40% 12.11B
Average +0.81%+1.60%+59.80%+94.58% 23.61B
Weighted average by Cap. +1.05%+1.76%+60.10%+103.18%

Financials

2024 2025
Net sales 673M 4.2M 3.62M 3.33M 3.13M 5.87M 397M 5.93M 39.41M 15.39M 194M 15.77M 15.44M 1.36B 8.47M 7.3M 6.72M 6.31M 11.84M 801M 11.96M 79.46M 31.04M 392M 31.8M 31.12M
Net income -641M -4M -3.45M -3.17M -2.98M -5.59M -378M -5.65M -37.53M -14.66M -185M -15.02M -14.7M 205M 1.28M 1.1M 1.02M 953K 1.79M 121M 1.81M 12M 4.69M 59.24M 4.8M 4.7M
Net Debt -1.77B -11.03M -9.51M -8.75M -8.21M -15.42M -1.04B -15.58M -103M -40.42M -511M -41.41M -40.53M -1.45B -9.04M -7.79M -7.17M -6.73M -12.64M -855M -12.76M -84.79M -33.12M -418M -33.93M -33.21M
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!